D Mannose in Recurrent Urinary Tract Infections

Recurrent Urinary Tract Infection Clinical Trial

Official title:

Recurrent Urinary Tract Infections in Adult Women: a Pilot Study With Oral D Mannose

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01808755
• Other study ID #: DMannose UTIs
• Status: Completed
• Phase: Phase 3
• First received: March 7, 2013
• Last updated: April 25, 2014
• Start date: January 2012
• Est. completion date: October 2012

Study information

• Verified date: April 2014
• Source: IRCCS Policlinico S. Matteo
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Background- In recurrent urinary tract infections (RUTIs) usual prophylactic antibiotic regimes do not change the long term risk of recurrence.

Objective- D-Mannose is a sugar, it sticks to E. coli bacteria, the aim of the study was to evaluate its efficacy in the treatment and prophylaxis of recurrent UTIs.

Design, setting and participants- : In this crossover trial female patient were eligible for the study if they had recurrent UTIs, that is three ore more episodes during the preceding 12 months. Suitable patients were randomly assigned to antibiotic treatment with trimethoprim/sulfamethoxazole or to a regimen of oral D Mannose for 24 weeks, and received the other intervention in the second phase of the study.

Outcome measurements and statistical analysis- The time to recurrence of UTI, bladder pain (VAS p) and urinary urgency (VAS u) were evaluated at the end of antibiotic therapy and at the and of 24 weeks fo D Mannose. The results for quantitative variables were expressed as mean values and SD as they were all normally distributed (Shapiro-Wilk test). T-test for paired data was used to analyze differences of time of recurrence, VAS pain, Vas urgency and number of voidings between treatment. Data analysis was performed with STATA statistical package (release 11,1, 2010, Stata Corporation, College Station, Texas, USA).

Description:

INTRODUCTION Urinary tract infections (UTIs) are among the most common infectious diseases, with a substantial financial burden to society. In Europe data on the presence of various types of UTIs indicate a high impact on quality of life of people affected, it is important the impact of urinary tract infections on the economy in general and on the health system in particular. In the U.S. urinary tract infections account for more than 7 million doctor visits each year, including more than 2 million visits for cystitis. The bacterium E. coli, which is the source of 90% of urinary tract infections, shows an incredible ability to survive in the human body, and is able to change rapidly to survive antibiotics. An infection of the urinary tract must be stopped before it begins to migrate to the kidneys, where it can cause serious infections. Women with frequent reinfections have a rate of 0.13 to 0.22 UTIs per month (1.6 to 2.6 infections per year). For premenopausal, healthy, and active females, recurrent UTIs are a major healthcare concern. Recurrent urinary tract infection (RUTI) is defined as three episodes of urinary tract infection (UTI) with 3 positive urine cultures in the previous 12 months or two episodes in the last six months. The usual present strategies employing a prophylactic antibiotic regime to prevent recurrent UTIs include long-term low-dose prophylactic antimicrobial treatment or postcoital antibiotic treatment. However, it seems that these strategies do not alter the long-term risk of recurrence. Patients with frequent UTIs who take prophylactic antimicrobial agents for extended periods decrease their infections during prophylaxis, but the rate of infection returns to pre-treatment rates when prophylaxis is stopped . Long-term antibiotics do not appear to positively affect the patient's basic susceptibility to infections. The cell wall of E. coli bacteria has tiny finger-like projections that contain complex molecules called lectins on their surface. These lectins act as a cellular glue that binds the bacteria to the bladder wall so they cannot be easily rinsed out by urination . In this pilot study the aim was to evaluate if oral D Mannose could be used as a safe and effective treatment and as a prophylactic measure for recurrent UTIs in adult women.

PATIENTS AND METHODS Suitable female patients with recurrent urinary tract infections who were visited at the outpatient Clinic of our Urology Department were eligible for study. The work has been conducted in accordance with the principles of the Declaration of Helsinki of World Medical Association. Patients were enrolled in the study after treatment for the most recent urinary tract infection if they had positive urinary cultures at that time.

Each participant entering the trial was assigned to one of the following treatments in a random sequence:

1. A regimen of five-day antibiotic therapy with trimethoprim/sulfamethoxazole 160 mg/800 mg twice a day. Then 1 week of antibiotic every 4 weeks for the following 23 weeks

2. A regimen of oral D Mannose 1 gr. 3 times a day, every 8 hours for 2 weeks, and subsequently 1 gr. twice a day for 22 weeks. D-Mannose has the best activity when urine has neutral pH, therefore patients were instructed to measure urinary pH using dipsticks and use oral sodium bicarbonate 250 mg b.i.d.or potassium citrate 1 gr. b.i.d. as alkalinizing agents if pH was <7.

Patients were randomly assigned to antibiotic treatment with trimethoprim/sulfamethoxazole or to a regimen of oral D Mannose for 24 weeks, and received the other intervention in the second phase of the study.

VAS score for bladder pain (VASp) and for urgency (VASu) was evaluated before starting D Mannose and at 24 weeks. The 24 hour number of voidings was obtained filling a voiding diary before and at the end of treatment with D Mannose. Cure was defined as the resolution of symptoms and no post-treatment bacteriuria at the 24 week follow-up visit. Cure with recurrence was defined as having resolution of symptoms with negative cultures at 12 week followed by significant UTI with bacteriuria before 24 weeks. Failure was defined as having persistent symptoms and significant bacteriuria before 24 weeks. The cure rate was determined for patients who met infection criteria, returned for the follow-up visits and had been treated with an antimicrobial for recurrent urinary tract infection occurring twice or more times during the 6 months preceding the 24 weeks course of daily oral D Mannose. The time to recurrence of UTI, VAS pain and VAS urgency were evaluated at the end of antibiotic therapy and at the end of 24 week treatment with oral D Mannose. Statistical Analysis- The results for quantitative variables were expressed as mean values and SD as they were all normally distributed (Shapiro-Wilk test). T-test for paired data was used to analyze differences of time of recurrence, VAS pain, Vas urgency and number of voidings between treatment. Data analysis was performed with STATA statistical package (release 11,1, 2010, Stata Corporation, College Station, Texas, USA).

DISCUSSION- The approach in the management of recurrent urinary tract infections is usually to treat adequately an episode of infection and after the completion should document complete eradication with a urine culture; if infection reoccurs or persists then imaging is required. In the management of recurrent UTIs in women it is a common practice to fight the resistance of the bacterium E. coli by varying the type of antibiotics, or increasing the dose and duration of therapy. However, in doing so the bacteria become even more resistant to broad spectrum antibiotics. Moreover, the resistance of the bacterium would not increase if the infection was due to a new E. coli contamination of the faeces or to sexual contact. What actually appears to occur is the survival of a part of the old colony of bacteria in the urinary tract, they remain latent and are reactivated by various favourable conditions, the relentless recurrences are therefore not considered as reinfection. It could be learnt a lot from patients and from research done on the causes of repeated urinary tract infections, especially due to the bacterium E. coli. Uropathogenic Escherichia coli (UPEC) strains may contain virulence factors that allow the bacteria to penetrate into the transitional cells and form quiescent intracellular reservoirs (QIRs). Establishment of QIRs throughout the underlying transitional epithelium may predispose an individual to an increased likelihood of recurrence and may account for some of the frequent same-strain recurrences that are seen clinically despite appropriate antibiotic therapy. A difficult aspect of treating urinary tract infections in women is the high likelihood of recurrence. In a series of trials a group of susceptible women averaged 2.6 infections per patient per year despite the apparent effectiveness of short-term therapy. While long-term prophylaxis was relatively effective in that series, resistance to trimethoprim-sulfamethoxazole by urinary pathogens increased to 19% in a 5-year period. Although there is debate regarding the duration of antibiotic therapy, emergence of drug-resistant organisms has to be considered with prolonged antibiotic use, even in healthy women with uncomplicated UTIs. A number of triggers lead to the reactivation of dormant E.coli already in the bladder, or the release of E.coli pods from behind biofilms in the bladder. When a first UTI is caused by E. coli, the risk of a second infection within 6 months is greater than when a first infection is cause by another uropathogen. Although E. coli was the most frequently isolated microorganism in our group of patients, the limited number of patients studied could not confirm this assumption. The chemical structure of D-Mannose causes it to stick to E. coli bacteria, maybe even more tenaciously than E. coli adheres to human cells. Although the mechanism of how it works is complicated, theoretically, if enough D-mannose is present in the urine, it binds to the bacteria and prevents them from attaching to the urinary tract lining. Our clinical experience shows that D Mannose represents a useful choice to address the problem of recurrent UTIs. The time required to develop a new infection, or for the re-emergence of the bacterial reservoir, as can be assumed from new data, is significantly longer with a prolonged course of oral D Mannose than with antibiotic treatment, even when these are used for long periods at a low dose, or in cycles. We actually know mannose has no bactericidal properties, and it might well be that the dosage and duration of therapy have to be individualized according to bacterial growth and replication speed in the bladder and urinary tract. The major part of mannose ingested is eliminated with urine and works by binding to bacteria concentrated in infected urine and attempting to perpetuate infection by binding to mannose receptors of urothelial bladder cells, this mechanism being the one involved in most cases of recurrences. In most cases recurrences are wrongly regarded as re-infections: it is highly likely that bactericidal molecules not possessing the same properties cannot produce the same consistent effect, that is the elimination of more and more loads of bacteria with urine, "alive" albeit inactivated, motionless, devoid of pathogenic potential due to mannose linked to them.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: October 2012
• Est. primary completion date: October 2012
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 22 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients 18 years old or older

• 3 or more culture documented urinary tract infections in the preceding 12 months

• Patients who had not taken antimicrobials within 4 weeks and were not pregnant or contemplating pregnancy.

Exclusion Criteria:

• Patients with evidence of upper urinary tract infection, such as temperature higher than 38 °C, flank/lumbar pain or tenderness.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Communicable Diseases
• Infection
• Recurrent Urinary Tract Infection
• Urinary Tract Infections

Intervention

Dietary Supplement:
• D Mannose
1 gr. every 8 hours

Drug:
• trimethoprim/sulfamethoxazole
one cp b.i.d. for 5 days. Then one week of antibiotic every 4 weeks for the following 23 weeks

Locations

Country	Name	City	State
Italy	Urology Department Fondazione IRCCS Policlinico San Matteo	Pavia

Sponsors (1)

Lead Sponsor	Collaborator
IRCCS Policlinico S. Matteo

Country where clinical trial is conducted

Italy, 

References & Publications (3)

Mulvey MA, Lopez-Boado YS, Wilson CL, Roth R, Parks WC, Heuser J, Hultgren SJ. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science. 1998 Nov 20;282(5393):1494-7. Erratum in: Science 1999 Feb 5;283(5403):795. — View Citation

Mulvey MA, Schilling JD, Hultgren SJ. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun. 2001 Jul;69(7):4572-9. — View Citation

Mulvey MA, Schilling JD, Martinez JJ, Hultgren SJ. Bad bugs and beleaguered bladders: interplay between uropathogenic Escherichia coli and innate host defenses. Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):8829-35. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Days	time required to develop the next urinary tract infection; evaluation by means of urine analysis and urine culture	168	No

External Links

•   related reference